
Opinion|Videos|July 23, 2024
DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- DELLphi-301 Phase 2 Clinical Trial of Tarlatamab
- Please share your insights on the importance of ORR and DoR in patients with ES-SCLC who have relapsed or who are refractory to platinum-based chemotherapy.
- At the community practice level, does 90 days continue to mark platinum sensitivity status among patients with ES SCLC?
- What other factors contribute to the definition of treatment resistance in this patient subgroup?
- How clinically meaningful is a median OS of 14 months and a DoR of between 6 and 9 months in patients with relapsed or refractory ES SCLC?
- How do you weigh the risk-benefit ratio of treatment with tarlatamab in relapsed or refractory ES SCLC?
- To what degree might a Black Box warning on risk of CRS and ICANS impact ready adoption of this new therapy by community oncologists for their patients with progressive ES SCLC?
- Given that no fatal CRS or ICANS events were reported with the 10 mg dose and only one dose interruption was reported in Part 1 and 2 of the published Phase II study report, what is the potential to reduce patient monitoring time between bimonthly infusions of tarlatamab?
Advertisement
Related to this article

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

